Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Payables (2019 - 2025)

Cyclerion Therapeutics has reported Payables over the past 7 years, most recently at $480000.0 for Q3 2025.

  • Quarterly results put Payables at $480000.0 for Q3 2025, up 57.89% from a year ago — trailing twelve months through Sep 2025 was $480000.0 (up 57.89% YoY), and the annual figure for FY2024 was $390000.0, down 67.45%.
  • Payables for Q3 2025 was $480000.0 at Cyclerion Therapeutics, up from $462000.0 in the prior quarter.
  • Over the last five years, Payables for CYCN hit a ceiling of $4.9 million in Q2 2021 and a floor of $304000.0 in Q3 2024.
  • Median Payables over the past 5 years was $1.6 million (2022), compared with a mean of $1.9 million.
  • Biggest five-year swings in Payables: surged 214.7% in 2021 and later crashed 81.12% in 2024.
  • Cyclerion Therapeutics' Payables stood at $1.8 million in 2021, then soared by 62.47% to $3.0 million in 2022, then crashed by 59.66% to $1.2 million in 2023, then plummeted by 67.45% to $390000.0 in 2024, then grew by 23.08% to $480000.0 in 2025.
  • The last three reported values for Payables were $480000.0 (Q3 2025), $462000.0 (Q2 2025), and $483000.0 (Q1 2025) per Business Quant data.